check_circleStudy Completed

Postmenopause, Hormone Replacement Therapy

Study to assess safety of a hormone therapy preparation containing Drospirenone/Estradiol in women with concomitant disease and medication known to potentate the risk of hyperkalemia

Trial purpose

Please see attached Study Results Summary below.

Key Participants Requirements

Sex

N/A

Age

N/A

Trial summary

Enrollment Goal
230
Trial Dates
December 2001 - March 2003
Phase
Phase 3
Could I Receive a placebo
N/A
Products
Angeliq (E2/DRSP, BAY86-4891)
Accepts Healthy Volunteer
N/A

Primary Outcome

Secondary Outcome

Trial design

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety of the Hormone Replacement Therapy Combination Drug Product Drospirenone/Estradiol in Postmenopausal Women With Concomitant Disease and Medication Known to Potentiate the Risk of Hyperkalemia
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A